Trabectedin is FDA-approved for advanced liposarcoma and leiomyosarcoma and can deplete both macrophages and MDSC through TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis (47–49). This evidence concerns the gene TNFSF10 and liposarcoma.